Bold claim: Postpartum depression can be treated quickly without drugs, and a major study is testing if a noninvasive approach can change lives in days rather than weeks. But here's where it gets controversial: not everyone agrees that neuromodulation without medication is ready for broad clinical use. UMass Chan Medical School is one of four national sites taking part in a clinical trial funded by the Department of Defense to evaluate an invasive-free therapy for patients with treatment-resistant postpartum depression.
The therapy, SAINT neuromodulation therapy, was developed by Magnus Medical. It has already received FDA clearance for major depressive disorder and, in a previous double-blind controlled study, produced rapid remission in about 80 percent of participants with major depression. This combination of prior success and new application to postpartum depression raises hopes for a subset of women who struggle to find effective treatments.
"Postpartum depression can be devastating. A treatment that works in days rather than weeks could be life-changing for families," says Kimberly A. Yonkers, MD, the Katz Family Chair in Psychiatry, and the lead investigator at UMass Chan. Her team highlights that postpartum depression affects roughly one in eight women in the United States, with symptoms potentially arising during pregnancy or in the months after birth. While current options like antidepressants or psychotherapy exist, they often take weeks to produce noticeable relief and may pose breast-feeding considerations for new mothers.
The SAINT therapy uses brain imaging to identify mood-related regions and then delivers targeted neurostimulation. The process begins with an MRI to map individual brain areas, followed by 10-minute magnetic stimulation sessions. Participants receive 10 sessions per day for five days on an outpatient basis. Some individuals may experience symptom improvement within a week, and SAINT can be added to ongoing treatments if those treatments remain unchanged.
The new multisite trial will enroll up to 192 women aged 18 to 45 who meet the technical diagnosis of peripartum-onset major depressive disorder. UMass Chan will recruit 85 participants. If successful, this study could broaden access to a drug-free option for postpartum depression that may work faster than traditional approaches and complement existing therapies.
